Search Results
Feb 26, 2026, 08:48 ET FuriosaAI and Helikai Partner to Deliver Secure, Production-Ready Enterprise AI Automation Stack
domain–specific expertise, deterministic behavior, and immediate ROI.By running Helibots on Furiosa's RNGD hardware — which delivers 512 TOPS of INT8 compute at just 180W — organizations can deploy complex agentic workflows in environments where traditional GPU–based systems are impractical due to
More news about: Helikai, Inc.
Feb 25, 2026, 13:02 ET Die an der Euronext Amsterdam notierte SWI Stoneweg Icona Group steigt mit einer Mehrheitsbeteiligung an Polarise, einem führenden europäischen NVIDIA Cloud Partner, in den Bereich KI-Computing ein und schafft eine vollständig integrierte europäische KI-Infrastrukturplattform
ner-mehrheitsbeteiligung-an-polarise-einem-fuhrenden-europaischen-nvidia-cloud-partner-in-den-bereich-ki-computing-ein-und-schafft-eine-vollstandig-int-302697366.html
More news about: SWI Group
Feb 24, 2026, 09:00 ET Royal Biologics Announces Strategic Partnership with Jellagen (UK) to Bring Jellyfish-Derived Collagen Type Zero to the U.S. Regenerative Medicine Market
et al. In Vivo Analysis of the Biocompatibility and Immune Response of Jellyfish Collagen Scaffolds and its Suitability for Bone Regeneration. Int J Mol Sci. 2020 Jun 25;21(12):4518.Bowen A.J, et al. Larynx proteomics after jellyfish collagen IL: Increased ECM/collagen and suppressed
More news about: Royal Biologics
Feb 17, 2026, 07:00 ET Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
Faustman DL, Davis M, Kuhtreiber WM. TNFR2 Agonism: Basic Science and Promising Treatment for Multiple Sclerosis and Related Diseases. Int J Mol Sci. 2025 Aug 14;26(16):7839. doi: 10.3390/ijms26167839. PMID: 40869160; PMCID: PMC12386426.
More news about: Nektar Therapeutics
Feb 13, 2026, 18:01 ET Breakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression
(Csonka, G.I.; Papp, A.; Somlyai, I.; Somlyai, G. Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration. Int. J. Mol. Sci. 2025, 26, 10969. https://doi.org/10.3390/ijms262210969)
More news about: HYD LLC
Feb 13, 2026, 08:58 ET Intensity Therapeutics Announces Reverse Stock Split
any payments in cash in lieu of fractional shares, if applicable.About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Feb 10, 2026, 09:05 ET Neuspera Medical Announces Milestone Case of Traditional Sacral Neuromodulation (SNM) System Removed and Replaced With the Company's Integrated SNM System for Urinary Urge Incontinence
[email protected]:Bretschneider CE, et al. "Device-Related Reoperations 8 Years Following Sacral Neuromodulation Implantation in Older Women". Int Urogynecol J. 2024 Dec;35(12):2349-2355.Axonics Modulation Technologies, Inc. Form 10-K for the fiscal year ended October 5, 2018. U.S. Securities
More news about: Neuspera Medical
Feb 03, 2026, 08:00 ET AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
2.Krüger C, Schallreuter KU. Int J Dermatol. 2012;51(10):1206–123.
More news about: AbbVie
Jan 29, 2026, 09:25 ET CW Bancorp Reports Fourth Quarter 2025 and Full Year Financial Results
Int Bearing Due from Banks & FFS$
More news about: CW Bancorp
Jan 28, 2026, 09:00 ET First Community Corporation Announces Fourth Quarter and Year End 2025 Results and Cash Dividend
3.46 % Int bearing deposits in other banks166,018
More news about: First Community Corporation
Jan 26, 2026, 16:05 ET LINKBANCORP, Inc. Announces Fourth Quarter 2025 and Full Year 2025 Financial Results and Declares Dividend
Yield/RateInt. Earn. Cash
More news about: LINKBANCORP, Inc.
Jan 26, 2026, 14:30 ET Study Shows NanoFuse® Superiority: Why Bioactive Glass-DBM Composites Outperform DBM and Bioactive Glass Alone
Osteoinductive Potential of BMP-2, Bioactive Glass, and Demineralized Bone Matrix: An In Vitro Alkaline Phosphatase Assay Study," appears in Int J Spine Surg , Volume 19, Issue 6 (December 2025). Recombinant human BMP-2 was included in the study solely as a reference control to
More news about: NanoFUSE Biologics
Jan 25, 2026, 21:48 ET Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
doi:10.1038/s41467-021-23507-z.[2] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.[3] Hampel H, Hardy J, Blennow K, et al. The
More news about: BioArctic
Jan 25, 2026, 21:45 ET Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
doi:10.1038/s41467-021-23507-z.[2] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.[3] Hampel H, Hardy J, Blennow K, et al. The
More news about: BioArctic
Jan 25, 2026, 18:30 ET FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
doi:10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.Hampel H, Hardy J, Blennow K, et al. The amyloid-β pathway
More news about: Eisai Inc.
Jan 22, 2026, 08:10 ET Healthcare Triangle, Inc. Signs Definitive Agreement with Teyame AI LLC which is forecasted to generate $38M in incremental NTM Revenue and incremental NTM EBITDA of $5M in addition to expanding its SaaS Footprint in Europe and Latin America
is-forecasted-to-generate-38m-in-incremental-ntm-revenue-and-incremental-ntm-ebitda-of-5m-in-addition-to-expanding-its-saas-footprint-in-europe-and-la-302667586.htmlSOURCE Healthcare Triangle, Inc.
More news about: Healthcare Triangle, Inc.
Jan 21, 2026, 07:30 ET Keenova Marks 100K Peyronie's Disease Patients--a Major Milestone for an Often-Stigmatized Men's Health Condition
al. PLoS One. 2016;11(2):e0150157.DiBenedetti DB, Nguyen D, Zografoset L, et al. Adv Urol. 2011:282503.Hellstrom WJ. Int J Impot Res. 2003;15:S91-S92.Contacts:
More news about: Keenova Therapeutics
Jan 21, 2026, 05:00 ET File1099 Forms Online with ez1099 2025 No IRS TCC Needed
ez1099 20252025 Form 1099 Series - including 1099-A, 1099-B, 1099-C, 1099-CAP, 1099-DA , 1099-DIV, 1099-G, 1099-INT, 1099-K, 1099-LS, 1099-LTC, 1099-MISC, 1099-NEC, 1099-OID, 1099-PATR, 1099-Q, 1099-QA, 1099-R, 1099-S, 1099-SA, 1099-SB)2025 Form 1098
More news about: Halfpricesoft.com
Jan 21, 2026, 02:15 ET AM Group unterzeichnet wegweisende Absichtserklärung mit der Regierung von Uttar Pradesh zur Einrichtung eines GW-Scale-KI-Rechenzentrums, das die Demokratisierung der KI von Elektronenagenten bis hin zu intelligenten Tokens ermöglicht
content:https://www.prnewswire.com/news-releases/am-group-unterzeichnet-wegweisende-absichtserklarung-mit-der-regierung-von-uttar-pradesh-zur-einrichtung-eines-gw-scale-ki-rechenzentrums-das-die-demokratisierung-der-ki-von-elektronenagenten-bis-hin-zu-intelligenten-tokens-ermog-302666425.html
More news about: AM Group
Jan 20, 2026, 14:37 ET Zilliz Announces General Availability of Milvus 2.6.x on Zilliz Cloud, Powering Billion-Scale Vector Search at Even Lower Cost
Multilingual Retrieval for More AI Use Cases Milvus 2.6.x on Zilliz Cloud adds native support for spatial data, timezone-aware timestamps, INT8 vectors, and nested structures, alongside improved multilingual tokenization and phrase search—enabling complex, global AI applications
More news about: Zilliz
Jan 16, 2026, 06:49 ET Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
here.ReferencesSmith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143.Servais A, et al. Kidney Int. 2012;82(4):454-464.Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117.Tarragón, B, et al. Clin J Am Soc Nephrol 2024; 19(8)1005-1015.Data
More news about: Swedish Orphan Biovitrum AB
Jan 15, 2026, 17:00 ET New ez1099 efile Service Helps Businesses Meet Critical Deadlines!
ez1099 20252025 Form 1099 Series - including 1099-A, 1099-B, 1099-C, 1099-CAP, 1099-DA , 1099-DIV, 1099-G, 1099-INT, 1099-K, 1099-LS, 1099-LTC, 1099-MISC, 1099-NEC, 1099-OID, 1099-PATR, 1099-Q, 1099-QA, 1099-R, 1099-S, 1099-SA, 1099-SB)2025 Form 1098
More news about: Halfpricesoft.com
Jan 15, 2026, 09:00 ET Playlist and EGYM Announce Agreement to Merge and $785 Million in New Equity Investments, Bringing Together Global Leaders in Fitness and Wellness Technology
egym.com/int.About Affinity PartnersAffinity Partners is a Miami-based investment firm founded in 2021 by Jared Kushner. With over $5.7B
More news about: Playlist
Jan 14, 2026, 09:00 ET Monetizing Sustainability: How Environmental Assets Are Driving Profitable Opportunities
renewable fuel platform and aligns with its recently signed non-binding Memorandum of Understanding ("MOU") with global energy and commodities group BGN INT US LLC ("BGN"). As contemplated by the MOU, subject to the negotiation of a definitive agreement, XCF and BGN intend to jointly develop global distribution,
More news about: Market News Updates
Jan 13, 2026, 07:47 ET Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
progress INT230-6 across multiple development pathways, in an attempt to build long-term shareholder value through consistent execution."About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was
More news about: Intensity Therapeutics Inc.